COMMUNIQUÉS West-GlobeNewswire

Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
25/02/2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's [...]
ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
25/02/2026
Garching / Munich, February 25, 2026 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that it will provide further exploratory and post-hoc subgroup analysis [...]
Rgenta Therapeutics Presents Preclinical Data, Unveiling its New Drug Candidate, RGT-0474060, as a Promising Oral PMS1 Inhibitor for the Treatment of Huntington’s Disease
25/02/2026
Data demonstrating superior selectivity, safety and pharmacokinetics of RGT-0474060 were presented at the 21 st Annual Huntington’s Disease Therapeutics Conference (CHDI) being held this week in Palm Springs, CA Rgenta [...]
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
25/02/2026
100% complete response (CR) rate among all six efficacy evaluable patients Favorable safety profile with no Grade > 3 CRS or ICANS Prior investigator-initiated trial (IIT) reached median progression free survival ( [...]
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
25/02/2026
NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Medline Reports Fourth Quarter and Full Year 2025 Results
25/02/2026
Delivered strong full year 2025 results Completed Initial Public Offering Introduced full year 2026 guidance Fourth quarter net sales of $7.8 billion, an increase of 14.8% Fourth quarter net income of $180 million, a [...]
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
25/02/2026
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE [...]
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
25/02/2026
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
25/02/2026
Unlocks market access and growth potential of REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer by enabling adoption and utilization tracking HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus [...]
Kura Oncology to Participate in Three Upcoming Investor Conferences
25/02/2026
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its [...]
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
25/02/2026
BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the [...]
Century Therapeutics to Participate in Upcoming Investor Conferences in March
25/02/2026
PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
Effective Oral Steroids For Strength & Muscle Growth 2026: Legal Steroids For Sale" Smart Bodybuilders Use Crazy Bulk Steroid Alternatives.
25/02/2026
Legal Steroids For Sale 2026: Launched By Crazy Bulk" Steroids Alternatives for Cutting, Bulking, Body Building & Muscle Growth Safe Oral Steroids For Strength in USA. New York City, Feb. 25, 2026 (GLOBE NEWSWIRE [...]
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
25/02/2026
Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous [...]
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
25/02/2026
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of [...]
Upstream Bio to Participate in Upcoming March Investor Conferences
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies [...]
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
25/02/2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
25/02/2026
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]

Pages